Last reviewed · How we verify
Placebo (PBO) oral capsules
Placebo (PBO) oral capsules is a Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 3 development for Control arm in phase 3 clinical trials (non-therapeutic use).
Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.
Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit. Used for Control arm in phase 3 clinical trials (non-therapeutic use).
At a glance
| Generic name | Placebo (PBO) oral capsules |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo works through psychological and neurobiological mechanisms including expectation, conditioning, and activation of endogenous pain-relief and reward pathways. It is used as a control comparator in clinical trials to distinguish the true pharmacological efficacy of an investigational drug from non-specific effects. Placebo can produce measurable clinical improvements in subjective symptoms, particularly pain, nausea, and fatigue, through mind-body interactions.
Approved indications
- Control arm in phase 3 clinical trials (non-therapeutic use)
Common side effects
- Placebo effect (symptom improvement without active drug)
Key clinical trials
- Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder (NA)
- Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study (PHASE4)
- Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study (PHASE1)
- Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression (PHASE2)
- Evaluation of Immediate-Release Viloxazine in Adults With ADHD (PHASE1, PHASE2)
- Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection (PHASE2)
- A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) (PHASE3)
- Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (PBO) oral capsules CI brief — competitive landscape report
- Placebo (PBO) oral capsules updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI